Functional imaging of head and neck cancers

Current Opinion in Oncology

Volumn 21, Issue 3, 2009, Pages 212-217

  Emonts, Patrick ^a   Bourgeois, Pierre ^a   Lemort, Marc ^a   Flamen, Patrick ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Functional imaging; Head and neck cancer; Magnetic resonance imaging; Positron emission tomography

Indexed keywords

CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; DRUG UPTAKE; HEAD AND NECK CANCER; HUMAN; LARYNGOSCOPY; LYMPH NODE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; SCINTIGRAPHY; SENTINEL LYMPH NODE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SQUAMOUS CELL CARCINOMA; HEAD AND NECK TUMOR; SENSITIVITY AND SPECIFICITY;

CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 67650388371     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32832a2322     Document Type: Review

References (36)

1. Kyzas PA, Evangelou E, Denaxa-Kyza D, Ioannidis JP. 18F- fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst 2008; 100:712-720. A meta-analysis on FDG-PET for initial staging of HNSCC. Overall, FDG-PET sensitivity was 79% and specificity was 86%. However, in patients without clinical signs of lymph node involvement (cN0), sensitivity of FDG-PET was only 50%.
2. Alvarez Amézaga J, Barbier Herrero L, Pijoan del Barrio JI, et al. Diagnostic efficacy of sentinel node biopsy in oral squamous cell carcinoma. Cohort study and meta-analysis. J Med Oral Patol Oral Cir Bucal 2007; 12:E235-E243. A meta-analysis on the use of SLN scintigraphy for initial staging of locoregional lymph node involvement in OSCC. This study confirmed the feasibility and the efficacy of the technique.
3. Civantos F Jr, Zitsch R, Bared A, Amin A. Sentinel node biopsy for squamous cell carcinoma of the head and neck. J Surg Oncol 2008; 97:683-690.
4. Civantos F, Zitsch R, Bared A. Sentinel node biopsy in oral squamous cell carcinoma. J Surg Oncol 2007; 96:330-336.
5. Hornstra MT, Alkureishi LW, Ross GL, et al. Predictive factors for failure to identify sentinel nodes in head and neck squamous cell carcinoma. Head Neck 2008; 30:858-862.
6. Keski-Säntti H, Kontio R, Törnwall J, et al. Sentinel lymph node biopsy or elective neck dissection for patients with oral squamous cell carcinoma? Eur Arch Otorhinolaryngol 2008; 265 (Suppl 1):S13-S17.
7. Atula T, Shoaib T, Ross GL, et al. How many sentinel nodes should be harvested in oral squamous cell carcinoma? Eur Arch Otorhinolaryngol 2008; 265 (Suppl 1):S19-S23.
8. Keski-Säntti H, Mätzke S, Kauppinen T, et al. Sentinel lymph node mapping using SPECT-CT fusion imaging in patients with oral cavity squamous cell carcinoma. Eur Arch Otorhinolaryngol 2006; 263:1008-1012.
9. Hart RD, Henry E, Nasser JG, et al. Sentinel node biopsy in N0 squamous cell carcinoma of the oral cavity and oropharynx in patients previously treated with surgery or radiation therapy: a pilot study. Arch Otolaryngol Head Neck Surg 2007; 133:806-809.
10. Wagner A, Kermer C, Zettinig G, et al. Validity of sentinel lymph node (SLN) detection following adjuvant radiochemotherapy (RCT) in head and neck squamous cell carcinoma (HNSCC). Technol Cancer Res Treat 2007; 6:655-660.
11. Kowalski LP, Bagietto R, Lara JR, et al. Factors influencing contralateral lymph node metastasis from oral carcinoma. Head Neck 1999; 21:104-110.
12. Liao CT, Chang JT, Wang HM, et al. Pretreatment primary tumour SUVmax measured by FDG-PET and pathologic tumour depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int J Radiat Oncol Biol Phys 2009; 73:764-771.
13. Suzuki H, Hasegawa Y, Terada A, et al. FDG-PET predicts survival and distant metastasis in oral squamous cell carcinoma. Oral Oncol 2008. [Epub ahead of print]
14. Machtay M, Natwa M, Andrel J, et al. Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck 2009; 31:195-201.
15. Vernon MR, Maheshwari M, Schultz CJ, et al. Clinical outcomes of patients receiving integrated PET/CT-guided radiotherapy for head and neck carcinoma. Int J Radiat Oncol Biol Phys 2008; 70:678-684.
16. Isles MG, McConkey C, Methane HM. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008; 33:210-222.
17. Brouwer J, de Bree R, Comans EF, et al. Improved detection of recurrent laryngeal tumor after radiotherapy using (18)FDG-PET as initial method. Radiother Oncol 2008; 87:217-220.
18. de Bree R, Putten LV, Brouwer J, et al. Detection of locoregional recurrent head and neck cancer after (chemo)radiotherapy using modern imaging. Oral Oncol 2008. [Epub ahead of print]
19. van Hooren AC, Brouwer J, de Bree R, et al. The cost-effectiveness of (18)FDG-PET in selecting patients with suspicion of recurrent laryngeal carcinoma after radiotherapy for direct laryngoscopy. Eur Arch Otorhinolaryngol 2008. [Epub ahead of print] This important study shows that the implementation of FDG-PET in patients with suspected recurrent HNSCC is cost-effective.
20. Yao M, Smith RB, Hoffman HT, et al. Clinical significance of postradiotherapy [(18)F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer: a long-term outcome report. Int J Radiat Oncol Biol Phys 2008. [Epub ahead of print]
21. Lemort M, Canizares AC, Kampouridis S. Advances in imaging head and neck tumours. Curr Opin Oncol 2006; 18:234-239.
22. Abdel Razek AA, Sadek AG, Kombar OR, et al. Role of apparent diffusion coefficient values in differentiation between malignant and benign solitary thyroid nodules. AJNR Am J Neuroradiol 2008; 29:563-568.
23. Abdel Razek AA, Soliman NY, Elkhamary S, et al. Role of diffusion-weighted MR imaging in cervical lymphadenopathy. Eur Radiol 2006; 16:1468-1477.
24. Rubesova E, Grell AS, De Maertelaer V, et al. Quantitative diffusion imaging in breast cancer: a clinical prospective study. J Magn Reson Imaging 2006; 24:319-324.
25. Srinivasan A, Dvorak R, Perni K, et al. Differentiation of benign and malignant pathology in the head and neck using 3T apparent diffusion coefficient values: early experience. AJNR Am J Neuroradiol 2008; 29:40-44.
26. de Bondt RB, Hoeberigs MC, Nelemans PJ, et al. Diagnostic accuracy and additional value of diffusion-weighted imaging for discrimination of malignant cervical lymph nodes in head and neck squamous cell carcinoma. Neuroradiology 2009; 51:183-192. This interesting and well conducted study uses a node-by-node method for histopathologic correlation and addresses the problem of small nodes (<10 mm), which are the most challenging for preoperative diagnosis.
27. Hamstra DA, Lee KC, Moffat BA, et al. Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck. Transl Oncol 2008; 1:187-194. This preclinical study at high field (7 T) on an animal model of HNSCC gives experimental background to the use of diffusion for evaluating treatment response.
28. Kim S, Loevner LA, Quon H, et al. Monitoring response to chemoradiotherapy of squamous cell carcinoma of the head and neck using diffusion weighted MRI. In: Proceedings of 16th Annual Meeting of International Society for Magnetic Resonance in Medicine; 3-9 May 2008; Toronto, ON. p. 3465.
29. Vandecaveye V, De Keyzer F, Nuyts S, et al. Detection of head and neck squamous cell carcinoma with diffusion weighted MRI after (chemo)radiotherapy: correlation between radiologic and histopathologic findings. Int J Radiat Oncol Biol Phys 2007; 67:960-971.
30. Hermans R, Vandecaveye V. Diffusion-weighted MRI in head and neck cancer. Cancer Imaging 2007; 7:126-127.
31. O'Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007; 96:189-195.
32. Shah GV, Wesolowski JR, Ansari SA, Mukherji SK. New directions in head and neck imaging. J Surg Oncol 2008; 97:644-648.
33. Yankeelov TE, Luci JJ, Lepage M, et al. Quantitative pharmacokinetic analysis of DCE-MRI data without an arterial input function: a reference region model. Magn Reson Imaging 2005; 23:519-529.
34. Oberholzer K, Pohlmann A, Schreiber W, et al. Assessment of tumor microcirculation with dynamic contrast-enhanced MRI in patients with esophageal cancer: initial experience. J Magn Reson Imaging 2008; 27:1296-1301.
35. Newbold K, Castellano I, Charles-Edwards E, et al. An exploratory study into the role of dynamic contrast-enhanced magnetic resonance imaging or perfusion computed tomography for detection of intratumoral hypoxia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2008. [Epub ahead of print] 36 Lemort M, Canizares-Perez AC, Van der Stappen A, Kampouridis S. Progress in magnetic resonance imaging of brain tumours. Curr Opin Oncol 2007; 19:616-622.
36. Bisdas S, Baghi M, Wagenblast J, et al. Gadolinium-enhanced echo-planar T2-weighted MRI of tumors in the extracranial head and neck: feasibility study and preliminary results using a distributed-parameter tracer kinetic analysis. J Magn Reson Imaging 2008; 27:963-969. This is the first report using a first-pass MRI technique in HNSCC exploring tumour vascularity.